Aims: Thrombin is a critical element of crosstalk between pathways contributing to worsening of established heart failure (HF). The aim of this study is to explore the efficacy and safety of rivaroxaban 2.5 mg bid compared with placebo (with standard care) after an exacerbation of HF in patients with reduced ejection fraction (HF-rEF) and documented coronary artery disease. Methods: This is an international prospective, multicentre, randomized, double-blind, placebo-controlled, event-driven study of approximately 5000 patients for a targeted 984 events. Patients must have a recent symptomatic exacerbation of HF, increased plasma concentrations of natriuretic peptides (B-type natriuretic peptide ≥200 pg/mL or N-terminal pro–B-type n...
BACKGROUND: Although therapy with aspirin or aspirin plus a thienopyridine reduces the incidence of ...
BACKGROUNDHeart failure is associated with activation of thrombin-related pathways, which predicts a...
BACKGROUND: Warfarin is widely prescribed for patients with heart failure without level 1 evidence, ...
AimsThrombin is a critical element of crosstalk between pathways contributing to worsening of establ...
Aims Thrombin is a critical element of crosstalk between pathways contributing to worsening of estab...
AimsThrombin is a critical element of crosstalk between pathways contributing to worsening of establ...
Aims: Thrombin is a critical element of crosstalk between pathways contributing to worsening of ...
International audienceAbstract Aims Stroke is often a devastating event among patients with heart fa...
AimsStroke is often a devastating event among patients with heart failure with reduced ejection (HFr...
Importance: Whether anticoagulation benefits patients with heart failure (HF) in sinus rhythm is unc...
IMPORTANCE Whether anticoagulation benefits patients with heart failure (HF) in sinus rhythm is unce...
Objectives: This study investigated the effects of a mid-trial protocol amendment requiring elevate...
OBJECTIVES This study investigated the effects of a mid-trial protocol amendment requiring elevated ...
BACKGROUND Heart failure is associated with activation of thrombin-related pathways, which predicts ...
Aim Stroke is often a devastating event among patients with heart failure with reduced ejection (HFr...
BACKGROUND: Although therapy with aspirin or aspirin plus a thienopyridine reduces the incidence of ...
BACKGROUNDHeart failure is associated with activation of thrombin-related pathways, which predicts a...
BACKGROUND: Warfarin is widely prescribed for patients with heart failure without level 1 evidence, ...
AimsThrombin is a critical element of crosstalk between pathways contributing to worsening of establ...
Aims Thrombin is a critical element of crosstalk between pathways contributing to worsening of estab...
AimsThrombin is a critical element of crosstalk between pathways contributing to worsening of establ...
Aims: Thrombin is a critical element of crosstalk between pathways contributing to worsening of ...
International audienceAbstract Aims Stroke is often a devastating event among patients with heart fa...
AimsStroke is often a devastating event among patients with heart failure with reduced ejection (HFr...
Importance: Whether anticoagulation benefits patients with heart failure (HF) in sinus rhythm is unc...
IMPORTANCE Whether anticoagulation benefits patients with heart failure (HF) in sinus rhythm is unce...
Objectives: This study investigated the effects of a mid-trial protocol amendment requiring elevate...
OBJECTIVES This study investigated the effects of a mid-trial protocol amendment requiring elevated ...
BACKGROUND Heart failure is associated with activation of thrombin-related pathways, which predicts ...
Aim Stroke is often a devastating event among patients with heart failure with reduced ejection (HFr...
BACKGROUND: Although therapy with aspirin or aspirin plus a thienopyridine reduces the incidence of ...
BACKGROUNDHeart failure is associated with activation of thrombin-related pathways, which predicts a...
BACKGROUND: Warfarin is widely prescribed for patients with heart failure without level 1 evidence, ...